Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
7.623T
Market Weight
9.76%
Industries
11
Companies
1136
Healthcare S&P 500 ^GSPC
Chart Range Bar
Loading chart for Healthcare
Day Return
Sector
0.15%
S&P 500
0.28%
YTD Return
Sector
5.34%
S&P 500
0.50%
1-Year Return
Sector
13.80%
S&P 500
11.95%
3-Year Return
Sector
21.83%
S&P 500
68.22%
5-Year Return
Sector
26.72%
S&P 500
77.01%
Note: Sector performance is calculated based on the previous closing price of all sector constituents
Industries in This Sector
Select an Industry for a Visual Breakdown
| Industry | Market Weight | YTD Return | |
|---|---|---|---|
| All Industries | 100.00% | 5.34% | |
| Drug Manufacturers - General | 42.37% | 18.15% | |
| Biotechnology | 12.37% | 2.64% | |
| Medical Devices | 11.35% | -1.22% | |
| Diagnostics & Research | 9.58% | -6.69% | |
| Healthcare Plans | 7.55% | -7.60% | |
| Medical Instruments & Supplies | 6.64% | -3.61% | |
| Medical Distribution | 3.25% | 9.54% | |
| Medical Care Facilities | 3.17% | 9.87% | |
| Drug Manufacturers - Specialty & Generic | 2.58% | 2.50% | |
| Health Information Services | 1.15% | -37.63% | |
| Pharmaceutical Retailers | 0.00% | -15.81% | |
Note: Percentage % data on heatmap indicates Day Return
All Industries
--
Day Return --
Market Weight --
YTD Return --
Drug Manufacturers - General
-0.26%
Biotechnology
0.88%
Medical Devices
-0.79%
Diagnostics & Research
0.02%
Healthcare Plans
0.08%
Medical Instruments & Supplies
-0.33%
Medical Distribution
Medical Care Facilities
Drug Manufacturers - Specialty & Generic
0.43%
<= -3
-2
-1
0
1
2
>= 3
Largest Companies in This Sector
View MoreName | Last Price | 1Y Target Est. | Market Weight | Market Cap | Day Change % | YTD Return | Avg. Analyst Rating |
|---|---|---|---|---|---|---|---|
| 1,023.22 | 1,211.21 | 13.23% | 965.262B | +0.26% | -4.79% | Buy | |
| 246.91 | 232.50 | 8.15% | 595.028B | +0.78% | +19.31% | Buy | |
| 224.35 | 248.29 | 5.43% | 396.513B | -1.91% | -1.81% | Buy | |
| 121.86 | 124.89 | 4.17% | 304.38B | +0.16% | +15.77% | Buy | |
| 289.93 | 364.62 | 3.60% | 262.63B | +0.60% | -12.17% | Buy | |
| 375.50 | 347.00 | 2.77% | 202.42B | -1.11% | +14.72% | Buy | |
| 112.19 | 133.39 | 2.68% | 195.262B | -0.97% | -10.46% | Buy | |
| 515.12 | 666.46 | 2.65% | 193.535B | +0.30% | -11.10% | Buy | |
| 151.12 | 155.41 | 2.57% | 187.491B | -1.06% | +23.12% | Buy | |
| 499.53 | 611.82 | 2.43% | 177.398B | -0.25% | -11.80% | Buy |
Investing in the Healthcare Sector
Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds
ETF Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 157.26 | 40.98B | 0.08% | +1.59% | |
| 290.87 | 19.812B | 0.09% | +1.05% | |
| 175.03 | 8.534B | 0.44% | +3.71% | |
| 126.74 | 8.336B | 0.35% | +3.94% | |
| 100.77 | 4.621B | 0.40% | +3.46% |
Mutual Fund Opportunities
View MoreName | Last Price | Net Assets | Expense Ratio | YTD Return |
|---|---|---|---|---|
| 209.11 | 39.263B | 0.32% | +2.22% | |
| 88.17 | 39.263B | 0.32% | +2.23% | |
| 145.53 | 19.812B | 0.09% | +1.10% | |
| 134.20 | 15.226B | 0.00% | +0.74% | |
| 11.18 | 15.226B | 0.00% | +0.66% |
Healthcare Research
View MoreDiscover the Latest Analyst and Technical Research for This Sector
Analyst Report: ICU Medical, Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
RatingPrice TargetAnalyst Report: Charles River Laboratories International, Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company’s research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
RatingPrice TargetAnalyst Report: Bayer Aktiengesellschaft
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (39% of total sales in 2024) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (49% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice TargetAnalyst Report: Bayer Aktiengesellschaft
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (39% of total sales in 2024) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (49% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
RatingPrice Target
